Your browser is no longer supported. Please, upgrade your browser.
ICLR ICON Public Limited Company monthly Stock Chart
ICON Public Limited Company
Index- P/E30.70 EPS (ttm)6.17 Insider Own4.00% Shs Outstand52.57M Perf Week2.22%
Market Cap9.95B Forward P/E24.50 EPS next Y7.73 Insider Trans0.00% Shs Float51.97M Perf Month10.47%
Income333.30M PEG4.32 EPS next Q1.53 Inst Own94.10% Short Float1.13% Perf Quarter21.34%
Sales2.77B P/S3.59 EPS this Y16.90% Inst Trans-0.20% Short Ratio2.57 Perf Half Y10.55%
Book/sh30.03 P/B6.31 EPS next Y23.51% ROA11.70% Target Price199.14 Perf Year23.20%
Cash/sh- P/C- EPS next 5Y7.11% ROE21.50% 52W Range104.28 - 199.83 Perf YTD9.93%
Dividend- P/FCF- EPS past 5Y20.30% ROI19.40% 52W High-5.25% Beta0.86
Dividend %- Quick Ratio- Sales past 5Y13.30% Gross Margin29.30% 52W Low81.58% ATR4.99
Employees15100 Current Ratio- Sales Q/Q-10.80% Oper. Margin14.00% RSI (14)62.17 Volatility1.82% 2.88%
OptionableYes Debt/Eq0.22 EPS Q/Q-46.60% Profit Margin12.00% Rel Volume0.56 Prev Close189.74
ShortableYes LT Debt/Eq0.00 EarningsJul 22 AMC Payout0.00% Avg Volume227.72K Price189.34
Recom2.30 SMA202.41% SMA509.77% SMA20017.40% Volume128,641 Change-0.21%
Jul-24-20Downgrade BofA Securities Buy → Neutral
Apr-20-20Downgrade Robert W. Baird Outperform → Neutral $151
Mar-26-20Upgrade Barclays Equal Weight → Overweight
Mar-02-20Initiated Deutsche Bank Hold
Jan-27-20Downgrade SunTrust Buy → Hold $170 → $182
Jan-08-20Initiated Wells Fargo Equal Weight $180
Jan-07-20Initiated Citigroup Neutral $185
Sep-23-19Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Jul-26-19Upgrade UBS Sell → Neutral
Jan-25-19Upgrade Mizuho Neutral → Buy
Oct-26-18Upgrade Evercore ISI In-line → Outperform
Oct-09-18Initiated UBS Sell
Apr-03-18Downgrade Evercore ISI Outperform → In-line
Feb-15-18Reiterated Mizuho Neutral $109 → $114
Jan-19-18Initiated Evercore ISI Outperform $126
Oct-27-17Reiterated Barclays Equal Weight $108 → $120
Sep-11-17Initiated BofA/Merrill Buy $128
Jul-31-17Upgrade SunTrust Hold → Buy
Jul-27-17Reiterated Mizuho Neutral $104 → $108
Jun-29-17Upgrade Jefferies Hold → Buy
Jul-30-20 01:30PM  
Jul-27-20 08:29PM  
Jul-23-20 09:01PM  
Jul-22-20 07:35PM  
Jun-18-20 03:33PM  
Jun-11-20 08:05AM  
May-27-20 06:00AM  
May-26-20 11:40AM  
May-21-20 11:46AM  
May-13-20 06:00AM  
May-05-20 04:30AM  
Apr-22-20 08:55PM  
Apr-18-20 10:28AM  
Apr-10-20 07:51AM  
Apr-09-20 04:30AM  
Apr-03-20 09:05AM  
Apr-02-20 01:04PM  
Mar-23-20 09:56AM  
Mar-19-20 06:57PM  
Mar-15-20 10:01AM  
Mar-03-20 09:00AM  
Feb-21-20 07:09AM  
Feb-19-20 06:55PM  
Feb-12-20 12:31PM  
Jan-27-20 11:54AM  
Jan-22-20 07:46AM  
Jan-21-20 09:11AM  
Jan-17-20 09:15AM  
Jan-14-20 06:00AM  
Jan-13-20 08:30AM  
Jan-01-20 01:43PM  
Dec-08-19 06:22PM  
Dec-05-19 01:00PM  
Dec-04-19 12:14PM  
Nov-27-19 06:00AM  
Nov-14-19 08:30AM  
Oct-30-19 09:42AM  
Oct-29-19 03:03PM  
Oct-23-19 05:55PM  
Oct-17-19 04:28PM  
Oct-16-19 10:32AM  
Oct-15-19 12:11PM  
Oct-04-19 09:39AM  
Sep-13-19 06:00AM  
Sep-11-19 02:18PM  
Sep-03-19 04:15PM  
Aug-23-19 09:40AM  
Aug-20-19 07:03AM  
Aug-06-19 09:30AM  
Jul-31-19 08:49PM  
Jul-26-19 03:49PM  
Jul-25-19 10:23AM  
Jul-24-19 05:45PM  
Jul-17-19 10:32AM  
Jun-26-19 09:51AM  
Jun-24-19 07:00AM  
Jun-19-19 09:08AM  
Jun-13-19 11:18AM  
Jun-05-19 08:48AM  
May-23-19 09:00AM  
May-15-19 02:11AM  
May-13-19 09:35AM  
May-09-19 07:00AM  
May-03-19 01:23PM  
May-01-19 06:15PM  
Apr-24-19 10:33AM  
Apr-19-19 10:45PM  
Apr-16-19 10:21AM  
Mar-05-19 05:00AM  
Feb-27-19 07:25AM  
Feb-26-19 02:11PM  
Feb-22-19 08:56AM  
Feb-21-19 10:00AM  
Feb-20-19 05:40PM  
Feb-13-19 10:31AM  
Feb-05-19 03:00AM  
Jan-22-19 01:19PM  
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.